Vanda Pharmaceuticals Inc.
VNDA Nasdaq
SEC CIK 1347178
Follow Vanda Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$69.8M
+24.1% vs same quarter last year
Net income
−$22.6M
+0.1% vs same quarter last year
EPS, diluted
−$0.37
+2.6% vs same quarter last year
Operating cash flow
−$28.4M
+10.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $216.1M | −$220.5M |
| FY24 | $198.8M | −$18.9M |
| FY23 | $192.6M | $2.5M |
| FY22 | $254.4M | $6.3M |
| FY21 | $268.7M | $33.2M |
| FY20 | $248.2M | $23.3M |
| FY19 | $227.2M | $115.6M |
| FY18 | $193.1M | $25.2M |
| FY17 | $165.1M | −$15.6M |
| FY16 | $146M | −$18M |
| FY15 | $109.9M | −$39.9M |
| FY14 | $50.2M | $20.2M |
| FY13 | $33.9M | −$21.1M |
| FY12 | $32.7M | −$28.6M |
| FY11 | $31.3M | −$9.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −70% | −102% |
| FY24 | - | −20.5% | −9.5% |
| FY23 | - | −7.2% | 1.3% |
| FY22 | - | 2.5% | 2.5% |
| FY21 | - | 15.7% | 12.4% |
| FY20 | - | 11% | 9.4% |
| FY19 | - | 10% | 50.9% |
| FY18 | - | 11.3% | 13.1% |
| FY17 | - | −10.2% | −9.4% |
| FY16 | - | −12.7% | −12.3% |
| FY15 | 78.7% | −36.6% | −36.3% |
| FY14 | 96.8% | 40% | 40.2% |
| FY13 | - | −62.6% | −62.1% |
| FY12 | 99.6% | −89.2% | −87.4% |
| FY11 | - | −34.2% | −31.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$110.4M |
| FY24 | −$16.2M |
| FY23 | $12.4M |
| FY22 | $31.3M |
| FY21 | $63.7M |
| FY20 | $50M |
| FY19 | $44.9M |
| FY18 | $29.6M |
| FY17 | −$3.6M |
| FY16 | −$9.5M |
| FY15 | $9.9M |
| FY14 | −$82.3M |
| FY13 | −$39.8M |
| FY12 | −$46.9M |
| FY11 | −$28.7M |
- Vanda Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Vanda Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −102% | −30.6% |
| FY24 | −9.5% | −47% |
| FY23 | 1.3% | −58% |
| FY22 | 2.5% | −80.4% |
| FY21 | 12.4% | −71.8% |
| FY20 | 9.4% | −62.2% |
| FY19 | 50.9% | −46.2% |
| FY18 | 13.1% | −49.6% |
| FY17 | −9.4% | −45.9% |
| FY16 | −12.3% | −36% |
| FY15 | −36.3% | −37.8% |
| FY14 | 40.2% | −35.5% |
| FY13 | −62.1% | −37.1% |
| FY12 | −87.4% | −29.1% |
| FY11 | −31.3% | −27.9% |